Please use this identifier to cite or link to this item:

http://hdl.handle.net/10609/92581
Title: Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial
Author: Luciano Devis, Juan Vicente
D'Amico, Francesco
Cerdà Lafont, Marta
Peñarrubia María, María Teresa
Knapp, Martin
Cuesta Vargas, Antonio Ignacio
Serrano Blanco, Antoni
García Campayo, Javier
Others: Universidad de Málaga
London School of Economics and Political Science
Universitat Oberta de Catalunya (UOC)
Keywords: cognitive behavioral therapy
usual care
fibromyalgia
pregabalin
duloxetine
Issue Date: 1-Oct-2014
Publisher: Arthritis Research and Therapy
Citation: Luciano Devis, J.V., D'Amico, F., Cerdà-Lafont, M., Peñarrubia-María, M.T., Knapp, M., Cuesta-Vargas, A.I., Serrano Blanco, A. & García-Campayo, J. (2014). Cost-utility of cognitive behavioral therapy versus U.S. food and drug administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Arthritis Research and Therapy, 16(1). doi: 10.1186/s13075-014-0451-y
Also see: https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-014-0451-y
Abstract: Cognitive behavioral therapy (CBT) and U.S. Food and Drug Administration (FDA)-recommended pharmacologic treatments (RPTs; pregabalin, duloxetine, and milnacipran) are effective treatment options for fibromyalgia (FM) syndrome and are currently recommended by clinical guidelines. We compared the cost-utility from the healthcare and societal perspectives of CBT versus RPT (combination of pregabalin + duloxetine) and usual care (TAU) groups in the treatment of FM.
Language: English
URI: http://hdl.handle.net/10609/92581
ISSN: 1478-6362MIAR
Appears in Collections:Articles
Articles

Share:
Export:
Files in This Item:
File Description SizeFormat 
costutility.pdf763.27 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons